Home Antibody All anti-AKT1 antibodies
Anti-AKT1 Antibody Y89
Also for AKT1 (NM_001014432)
|A synthetic peptide corresponding to residues in C-terminus of human Akt1 was used as immunogen. Predicted to cross-react with mouse, rat and bovine, based on sequence homology.|
||Lot dependent; please refer to CoA along with shipment
|WB, IHC, IF, FC
||ICC/IF: 1:100 - 1:250; WB: 1:5000 - 1:10000; IHC-P: Use at an assay dependent dilution; FC: 1:20; IP: 1:100
|PBS 49%,Sodium azide 0.01%,Glycerol 50%,BSA 0.05%|
|Protein A purified
|Homo sapiens v-akt murine thymoma viral oncogene homolog 1 (AKT1), transcript variant 2|
|AKT; CWS6; PKB; PKB-ALPHA; PRKBA; RAC; RAC-ALPHA|
|The serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq]. |
Delta-Notch Signaling Pathway
EGFR1 Signaling Pathway
Jak-STAT signaling pathway
MAPK signaling pathway
Signaling by GPCR
Toll-like receptor signaling pathway
Wnt Signaling Pathway
* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot - AKT1 antibody [Y89]; Anti-AKT1 antibody [Y89] at 1/10000 dilution + MCF-7 cell lysate.Predicted band size : 56 kDa.Observed band size : 59 kDa .
Immunohistochemistry (Paraffin-embedded sections) - AKT1 antibody [Y89]; Immunohistochemical analysis of paraffin-embedded prostate carcinoma using TA303387 at 1/100 dilution.
Immunocytochemistry/ Immunofluorescence - Anti-AKT1 antibody [Y89]; TA303387 staining AKT1 in SK-N-SH cells treated with alsterpaullone , by ICC/IF. Decrease of AKT1 expression correlates with increased concentration of alsterpaullone, as described in literature.The cells were incubated at 37Â°C for 6h in media containing different concentrations of (alsterpaullone) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with TA303387 (1/200 dilution was performed overnight at 4Â°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
Flow Cytometry-AKT1 antibody [Y89](TA303387); Overlay histogram showing HeLa cells stained with TA303387 (red line). The cells were fixed with methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody for 30 min at 22°C. The secondary antibody used was DyLight 488 goat anti-rabbit IgG (H+L) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was rabbit monoclonal IgG (1ug/1x10^6 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a slightly decreased signal in HeLa cells fixed with 4% paraformaldehyde (10 min)/permeabilized in 0.1% PBS-Tween used under the same conditions.